Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_00919 |
| Species: | Homo sapiens |
| Position : | chr8:55269891-55269990 |
| Year: | 2023 |
| Title: | SOX17 Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary Hypertension. |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | pulmonary arterial hypertension |
| PMID: | 37066790 |
| MONDO: | MONDO:0015924 |
| Tissue: | pulmonary artery endothelium |
| Tissue Ontology ID: | UBERON:0005317 |
| Cell Source: | primary human pulmonary artery endothelial cells (hPAECs) |
| Cell Type: | pulmonary artery endothelial cell |
| Cell Ontology ID: | CL:1001568 |
| Experiment Type: | Allele-specific enhancer activity; TF-binding assay; endogenous enhancer perturbation; disease-mechanism validation; Disease-variant functional analysis; In vivo functional validation |
| High Throughput Method: | RNA-seq; PAH GWAS/WGS fine-mapping and endothelial epigenomic integration from discovery study; GWAS |
| Low Throughput Method: | 100-bp allele-specific luciferase reporter; CRISPR deletion/CRISPRi; EMSA/supershift; HOXA5 ChIP-qPCR; SOX17 expression assays; endothelial functional assays; enhancer-knockout mouse PH phenotyping; siRNA knockdown; Mouse genetic deletion/knock-in; In vivo phenotyping |
| Target gene : | SOX17 |
| TF name : | HOXA5 |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|
| Enhancer ID | Position | Tissue | Cell | Disease |
|---|---|---|---|---|
| E_00915 | chr8:55269891-55269990 | pulmonary artery endothelium | pulmonary artery endothelial cell | pulmonary arterial hypertension |
| E_00920 | chr8:55269891-55269990 | pulmonary artery endothelium | pulmonary artery endothelial cell | pulmonary arterial hypertension |
| E_00921 | chr8:55269891-55269990 | pulmonary artery endothelium | pulmonary artery endothelial cell | pulmonary arterial hypertension |